Login to Your Account



Clinic Roundup


Friday, March 1, 2013

• Prima BioMed Ltd., of Sydney, Australia, said it started recruiting patients in its CANVAS (CANcer VAccine Study) Phase II/III trial in Europe to test CVac for the maintenance treatment of newly diagnosed, late-stage epithelial ovarian cancer in patients who achieve remission after optimal debulking surgery and standard first-line chemotherapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription